Table 1 Baseline characteristics of the GCS > 8 and GCS ≤ 8 groups. BMI (body mass index), ALB(album), ALT(alanine aminotransferase), AST(aspartate aminotransferase), BUN (blood urea nitrogen), CK( creatine kinase), CKMB(creatine kinase lsoenzyme MB), SCR (serum creatinine), GLU(glucose), HB(hemoglobin), HbA1c (hemoglobin a1c), TBIL(Total Bilirubin), TC (total cholesterol), TG (triglyceride), WBC((white blood cell), AF(Atrial Fibrillation), CHD(coronary heart disease), CKD(chronic kidney disease), DM(diabetes, HF(heart failure), HBP(high blood pressure), HL(hyperlipidemia), RF(respiratory failure), APSIII (acute physiology score III), SOFA (sequential organ failure assessment), OASIS, SAPSII(simplified acute physiological score II), AG(anion gap), ACAG(Albumin Corrected Anion Gap). 1n (%); Median [25-75%].2*p < 0.05; **p < 0.01; ***p < 0.001.
Characteristic | Overal, n = 23791 | GCS > 8,n = 19901 | GCS ≤ 8,n = 3891 | p-value2 |
---|---|---|---|---|
Hospital mortality | 275 (12%) | 128 (6.4%) | 147 (38%) | < 0.001*** |
In-hospital follow-up time, days | 6 [3–13] | 5 [3–10] | 16 [8–27] | < 0.001*** |
Long-term mortality | 845 (36%) | 608 (31%) | 237 (61%) | < 0.001*** |
Long-term follow-up time, days | 19 [4-187] | 17 [4-206] | 23 [9–82] | 0.008** |
Age, years | 71 [59–81] | 71 [60–81] | 69 [58–82] | 0.11 |
Gender | 0.8 | |||
Female | 1,175 (49%) | 981 (49%) | 194 (50%) | |
Male | 1,204 (51%) | 1,009 (51%) | 195 (50%) | |
BMI, kg/m2 | < 0.001*** | |||
Normal | 302 (13%) | 252 (13%) | 50 (13%) | |
Obese | 649 (27%) | 502 (25%) | 147 (38%) | |
Overweight | 358 (15%) | 303 (15%) | 55 (14%) | |
Underweight | 29 (1.2%) | 22 (1.1%) | 7 (1.8%) | |
Missing | 1,041 (44%) | 911 (46%) | 130 (33%) | |
Marital status | < 0.001*** | |||
Divorced | 162 (6.8%) | 143 (7.2%) | 19 (4.9%) | |
Married | 1,037 (44%) | 894 (45%) | 143 (37%) | |
Single | 594 (25%) | 498 (25%) | 96 (25%) | |
Widowed | 345 (15%) | 294 (15%) | 51 (13%) | |
Missing | 241 (10%) | 161 (8.1%) | 80 (21%) | |
Race | < 0.001*** | |||
Asian | 65 (2.7%) | 54 (2.7%) | 11 (2.8%) | |
Black | 317 (13%) | 273 (14%) | 44 (11%) | |
Other | 472 (20%) | 352 (18%) | 120 (31%) | |
White | 1,525 (64%) | 1,311 (66%) | 214 (55%) | |
ALB, g/dl | 3.70 [3.30-4.00] | 3.70 [3.30-4.00] | 3.30 [2.80–3.80] | < 0.001*** |
ALT, iu/l | 20 [14–33] | 19 [13–31] | 28 [17–54] | < 0.001*** |
AST, iu/L | 24 [18–40] | 23 [18–35] | 39 [24–85] | < 0.001*** |
BUN, mg/dl | 18 [13–25] | 17 [13–24] | 20 [14–31] | < 0.001*** |
CK, iu/l | < 0.001*** | |||
<47 | 214 (9.0%) | 185 (9.3%) | 29 (7.5%) | |
47–322 | 896 (38%) | 772 (39%) | 124 (32%) | |
>322 | 256 (11%) | 167 (8.4%) | 89 (23%) | |
Missing | 1,013 (43%) | 866 (44%) | 147 (38%) | |
CKMB, ng/mL | < 0.001*** | |||
<3.0 | 468 (20%) | 421 (21%) | 47 (12%) | |
3.0–10.0 | 630 (26%) | 522 (26%) | 108 (28%) | |
>10.0 | 165 (6.9%) | 91 (4.6%) | 74 (19%) | |
Missing | 1,116 (47%) | 956 (48%) | 160 (41%) | |
Chloride, mEq/L | 103 [100–106] | 103 [100–106] | 104 [100–108] | < 0.001*** |
SCR, mg/dL | 0.90 [0.70–1.20] | 0.90 [0.70–1.20] | 1.10 [0.70–1.50] | < 0.001*** |
GLU, mg/dL | 114 [96–150] | 111 [95–141] | 135 [107–186] | < 0.001*** |
HB, g/dL | 12.20 [10.55–13.60] | 12.30 [10.70–13.70] | 11.50 [10.00-12.90] | < 0.001*** |
HBA1C,% | < 0.001*** | |||
<6.5 | 1,199 (50%) | 1,076 (54%) | 123 (32%) | ≥ |
≥6.5 | 429 (18%) | 376 (19%) | 53 (14%) | |
Missing | 751 (32%) | 538 (27%) | 213 (55%) | |
HCO3,mEq/L | 24 [22–26] | 25 [22–27] | 23 [19–25] | < 0.001*** |
Potassium, mEq/L | 4.00 [3.80–4.40] | 4.00 [3.80–4.40] | 4.00 [3.70–4.50] | 0.4 |
Lymphocyte, k/uL | 0.020* | |||
<1.2 | 262 (11%) | 207 (10%) | 55 (14%) | |
1.2–1.7 | 157 (6.6%) | 133 (6.7%) | 24 (6.2%) | |
>1.7 | 205 (8.6%) | 184 (9.2%) | 21 (5.4%) | |
Missing | 1,755 (74%) | 1,466 (74%) | 289 (74%) | |
Sodium, mEq/L | 140 [137–142] | 140 [137–142] | 139 [137–142] | 0.8 |
Neutrophil, k/uL | < 0.001*** | |||
<1.6 | 22 (0.9%) | 19 (1.0%) | 3 (0.8%) | |
1.6–6.1 | 249 (10%) | 228 (11%) | 21 (5.4%) | |
6.1–8.6 | 145 (6.1%) | 123 (6.2%) | 22 (5.7%) | |
>8.6 | 208 (8.7%) | 154 (7.7%) | 54 (14%) | |
Missing | 1,755 (74%) | 1,466 (74%) | 289 (74%) | |
Platelet, k/uL | 212 [165–268] | 216 [168–269] | 198 [144–264] | < 0.001*** |
TBIL, mg/dL | 0.56 [0.40–0.80] | 0.50 [0.40–0.80] | 0.60 [0.40-1.00] | < 0.001*** |
TC, mg/dL | < 0.001*** | |||
<144 | 516 (22%) | 455 (23%) | 61 (16%) | |
144–199 | 692 (29%) | 637 (32%) | 55 (14%) | |
>199 | 378 (16%) | 356 (18%) | 22 (5.7%) | |
Missing | 793 (33%) | 542 (27%) | 251 (65%) | |
TG, mg/dL | < 0.001*** | |||
<87 | 522 (22%) | 469 (24%) | 53 (14%) | |
87–149 | 672 (28%) | 626 (31%) | 46 (12%) | |
>149 | 424 (18%) | 367 (18%) | 57 (15%) | |
Missing | 761 (32%) | 528 (27%) | 233 (60%) | |
WBC, k/uL | 8.6 [6.5–11.6] | 8.3 [6.4–11.1] | 10.6 [7.7–15.5] | < 0.001*** |
AF | 481 (20%) | 368 (18%) | 113 (29%) | < 0.001*** |
Alcohol use | 47 (2.0%) | 37 (1.9%) | 10 (2.6%) | 0.4 |
Anemia | 613 (26%) | 443 (22%) | 170 (44%) | < 0.001*** |
Cancer | 264 (11%) | 226 (11%) | 38 (9.8%) | 0.4 |
CHD | 697 (29%) | 552 (28%) | 145 (37%) | < 0.001*** |
CKD | 212 (8.9%) | 167 (8.4%) | 45 (12%) | 0.044* |
DM | 804 (34%) | 668 (34%) | 136 (35%) | 0.6 |
HF | 504 (21%) | 385 (19%) | 119 (31%) | < 0.001*** |
HBP | 1,270 (53%) | 1,084 (54%) | 186 (48%) | 0.016* |
HL | 687 (29%) | 601 (30%) | 86 (22%) | 0.001** |
RF | 421 (18%) | 202 (10%) | 219 (56%) | < 0.001*** |
Tobacco use | 164 (6.9%) | 132 (6.6%) | 32 (8.2%) | 0.3 |
Anticoagulant drugs | 2,047 (86%) | 1,784 (90%) | 263 (68%) | < 0.001*** |
Antiplatelet drugs | 1,649 (69%) | 1,480 (74%) | 169 (43%) | < 0.001*** |
APSIII | < 0.001*** | |||
<39 | 658 (28%) | 562 (28%) | 96 (25%) | |
≥39 | 672 (28%) | 379 (19%) | 293 (75%) | |
Missing | 1,049 (44%) | 1,049 (53%) | 0 (0%) | |
SOFA | < 0.001*** | |||
<1 | 579 (24%) | 450 (23%) | 129 (33%) | |
≥1 | 726 (31%) | 490 (25%) | 236 (61%) | |
Missing | 1,074 (45%) | 1,050 (53%) | 24 (6.2%) | |
OASIS | < 0.001*** | |||
<31 | 616 (26%) | 524 (26%) | 92 (24%) | |
≥31 | 714 (30%) | 417 (21%) | 297 (76%) | |
Missing | 1,049 (44%) | 1,049 (53%) | 0 (0%) | |
SAPSII | < 0.001*** | |||
<33 | 589 (25%) | 521 (26%) | 68 (17%) | |
≥33 | 605 (25%) | 406 (20%) | 199 (51%) | |
Missing | 1,185 (50%) | 1,063 (53%) | 122 (31%) | |
AG, mEq/L | 15.9 [13.5–18.2] | 15.8 [13.4–18.0] | 16.4 [13.9–19.1] | < 0.001*** |
ACAG, mEq/L | 17.9 [15.3–20.2] | 17.7 [15.2–19.9] | 19.1 [16.2–22.3] | < 0.001*** |
ACAG quartiles | < 0.001*** | |||
Q1 | 601 (25%) | 533 (27%) | 68 (17%) | |
Q2 | 605 (25%) | 524 (26%) | 81 (21%) | |
Q3 | 578 (24%) | 498 (25%) | 80 (21%) | |
Q4 | 595 (25%) | 435 (22%) | 160 (41%) |